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Abstract c-Myc is a transcriptional regulator involved in
carcinogenesis through its role in growth control and cell cycle
progression. Here we attempt to relate its role in stimulating the
G1^S transition to the ability to affect functioning of key cell
cycle regulators, and we focus on how its property of modulating
transcription of a wide range of target genes could explain its
capacity to affect multiple pathways leading to proliferation,
apoptosis, growth, and transformation. ß 2001 Federation of
European Biochemical Societies. Published by Elsevier Science
B.V. All rights reserved.
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1. Introduction
c-myc has been the object of ongoing interest since its iden-
ti¢cation as a cellular homolog of the transforming element in
the oncogenic retrovirus MC29. The c-Myc protein is a crit-
ical component for the control of normal cell growth, and is
the best studied member of a family that includes N-Myc, L-
Myc, S-Myc and B-Myc. The family seems to have evolved, in
part, to facilitate di¡erential expression patterns, since N-Myc
was shown to functionally replace c-Myc, when expressed
from the c-myc locus [1]. Altered myc activity by transloca-
tion, ampli¢cation, overexpression, and mutation is wide-
spread in tumor cells ; some of the best evidence for the
importance of altered Myc expression for multi-step
carcinogenesis comes from recent studies with inducible trans-
genes. Enforced expression of Myc in either skin or hemato-
poietic lineages in transgenic mice leads to neoplastic prema-
lignant and malignant phenotypes, respectively, but when
Myc expression is turned o¡, spontaneous regression of the
neoplastic changes occurs [2,3]. In recent years there has been
a revival of interest in the biology of Myc, as its role in cell
cycle regulation and the relevance of Myc-related apoptosis in
cancer came into focus. Also, the realization that Myc works
in a complex with Max to directly regulate transcription
stimulated considerable attention in mechanisms and targets
of transcriptional regulation, in relationship to Myc biological
function.
2. Myc biological activities
Myc function is not clari¢ed from classical knock-out stud-
ies, which demonstrated that both N-myc and c-myc are es-
sential for embryonic survival beyond day 10; Myc null em-
bryos are smaller, retarded in development, and show
pathological abnormalities in various organs [4]. Since there
may be cross-compensation, it is not clear whether c- or
N-Myc are necessary for proliferation of the embryonic
stem (ES) cells utilized for generating the embryos or for
embryo cells before day 10. Consistent with the central role
of Max in the Myc network, Max3/3 embryos die at an
earlier stage, around day 6, coincident with loss of maternal
storage of Max proteins [5]. Apparently ES cells can prolifer-
ate without Max. Generation of conditional myc knock-out
mice is expected to illuminate the function of Myc in prolif-
eration and development of distinct tissues. c-myc ablation in
¢broblasts or in B lineage cells has suggested that the c-Myc
protein is dispensable for survival, but is required for prolif-
eration upon stimulation with serum or cytokines, and that it
is linked to apoptotic pathways (I. Moreno de Alboran and
A. Trumpp, personal communication).
Myc is a strong inducer of proliferation, and its role in cell
cycle control has been intensively investigated as it is believed
to be critical for the oncogenic properties. However, it is still
unclear how altered cell cycle control by Myc contributes to
oncogenesis. Studies with rodent cell lines favored the view
that deregulated Myc expression drives cells inappropriately
through the cell cycle, leading to uncontrolled proliferation
characteristic of neoplastic cells. Studies with normal primary
¢broblasts and the analysis of transgenic mice expressing a
regulable Myc showed instead that Myc alone cannot sustain
the division cycle and suggested that a G2 checkpoint must be
eliminated for Myc to initiate continuous proliferation and
tumorigenesis. Upon Myc protein induction, normal ¢bro-
blasts are stimulated to pass through G1 and S phase, but
they are arrested in G2; this checkpoint is compromised by
the absence of p53 or its e¡ector p21. G2-arrested cells fre-
quently become aneuploid, possibly due to inappropriate re-
initiation of DNA synthesis. In this regard, Myc is di¡erent
from other oncoproteins like Ras, Raf, and E2F1, whose con-
tinuing activity causes a G1 block. Conditional Myc expres-
sion in keratinocytes of transgenic mouse epidermis drives
extensive proliferation, while proliferation in derma is blocked
by p53 (reviewed in [6]). In human epidermal keratinocytes,
c-Myc initially drives proliferation, and subsequently di¡er-
entiation, concomitant with activation of the p53 G2 check-
point [7]. In Drosophila, Myc overexpression was able to pre-
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vent a G1 block, but cells were still arrested in G2 by pattern-
ing signals from the Wingless pathway [8]. It is unclear how
sustained Myc expression activates the G2 checkpoint in
mammalian cells, but its capacity to indirectly cause induction
of ARF, and, consequently to stabilize p53 may be involved.
There is evidence that inactivation of the ARF/Mdm2/p53
pathway is required for immortalization through overexpres-
sion of Myc. The ability of Myc to activate telomerase reverse
transcriptase (hTERT), the rate-limiting enzyme in the telo-
merase complex, is clearly insu⁄cient to explain its capacity
to promote immortalization, since cells are prevented from
further proliferation unless the cell cycle checkpoint is abro-
gated. In mouse embryo ¢broblasts and during in vivo lym-
phomagenesis Myc activity appears to favor immortalization
indirectly, by promoting the selection of mutant cells that
inactivate the ARF/Mdm2/p53 pathway [9].
A connection between Myc deregulated expression and con-
trol of G2 progression is also observed when dMyc (Droso-
phila Myc) was overexpressed in developing wings: a G1
shortening caused by Myc induction was compensated by a
G2 increase, with no diminished cell proliferation [8]. The
major e¡ect of dMyc was to increase the growth rate, leading
to a greater cell mass, rather than to an increase in cell num-
ber. Since increase in cell mass (growth) and increase in cell
number (proliferation) are tightly coordinated in most tissues
[10], these data suggest either that Myc functions in coordi-
nating growth and proliferation or that its impact on cell
proliferation may be secondary to its role in control of
growth. Although various experiments con¢rmed that Myc
is involved in control of growth in mammals as well, they
failed to show the uncoupling between growth and prolifera-
tion observed in £ies following perturbation of Myc levels. In
conditional overexpression or knock-out studies, c-myc ap-
peared to be essential for proliferation of several mouse tis-
sues, without discernible e¡ects on cellular size ([6] and A.
Trumpp, personal communication). The small size of c-myc-
de¢cient embryos or conditionally de¢cient mice is likely due
to the concomitant reduction of growth and proliferation
rates, and, clearly, much is to be learned about the coordina-
tion of the two processes.
The fact that Myc controls growth, besides controlling cell
cycle progression, was also independently suggested by the
decrease in RNA and protein synthesis rates observed in
c-myc null ¢broblasts [11], which can still proliferate, although
at a signi¢cantly impaired rate. These cells have a three times
slower cell cycle, and both the G1 and G2 phases are signi¢-
cantly lengthened, whereas duration of the S phase is unaf-
fected. The rates of RNA and protein accumulation, as well as
protein degradation, are markedly reduced in a way that ex-
actly matches the lengthening of the cell cycle, so that c-myc
null cells have the same size, rRNA, and protein content as
their c-myc+/+ parents.
Myc activity is also known to a¡ect apoptosis and di¡er-
entiation [12]. Myc may favor an initial commitment from
proliferation to di¡erentiation [7]; however, Myc levels are
down-regulated during terminal di¡erentiation and enforced
Myc expression usually inhibits terminal di¡erentiation, pos-
sibly by interfering with cell cycle exit. Evidence suggests that
Myc sensitizes cells to a variety of apoptotic triggers rather
than directly inducing apoptosis by itself (reviewed in [13]).
This biological activity is mediated through cytochrome c re-
lease but requires other apoptotic signals such as those of
CD95/Fas and p53. The ability of Myc to concomitantly in-
duce proliferation and apoptosis in certain tissues can be con-
sidered a fail-safe mechanism against the unrestrained growth
of a cell with a single proliferative lesion [6].
Its ability to a¡ect such di¡erent aspects of cell behavior
can be in part related to the ¢nding that Myc participates in a
network of interacting proteins (Myc, Max, Mnt/Rox, Mga,
and the Mad family members Mad1, Mxi1/Mad2, Mad3, and
Mad4), all containing a basic helix-loop-helix^zipper motif
(bHLHZip) involved in dimerization and DNA binding.
Max holds a central position, since the other network proteins
depend on heterodimerization with Max in order to bind
DNA and regulate gene transcription (see [14] for review).
All dimers recognize in vitro the same E box binding site
CACGTG, but have distinct transcriptional activities. Myc/
Max dimers weakly activate transcription of promoters prox-
imal to E box sites; Max/Mad dimers repress transcription
from the same binding sites, by recruiting a Sin3^histone de-
acetylase complex. Overexpression of Myc/Max dimers in-
duces proliferation or apoptosis, while Max/Mad and Max/
Mnt complexes cause cell growth arrest and di¡erentiation
[15,16]. The equilibria among the various dimers are mainly
controlled through extracellular signal-induced modi¢cations
in Myc or Mad expression levels, the Max concentration re-
maining constant. Mad gene expression, which is usually low
in proliferating cells, is induced during cell di¡erentiation,
while c-myc transcription, which is regulated by tyrosine ki-
nase signalling and is rapidly turned on upon mitogenic stim-
ulation, is repressed [12,15]. The network can be viewed as a
functional module which acts to convert environmental sig-
nals into speci¢c gene-regulatory programs [14], and its basic
features are conserved in Drosophila, and possibly in Caeno-
rhabditis elegans, where only Max and Mad homologs were
reported [17].
3. Control of Myc expression in G1
c-myc is regulated by speci¢c growth signals in a cell cycle-
dependent manner, and its expression is tightly controlled at
di¡erent levels (Fig. 1). The relationship between c-myc ex-
pression and progression in G1 is evident when tissue culture
cells such as ¢broblasts or lymphocytes are stimulated to enter
the cell cycle. Transcription of c-myc, absent in quiescent cells,
is strongly induced within 1 h upon addition of growth factors
and cytokines like platelet-derived growth factor (PDGF),
colony-stimulating factor (CSF), epidermal growth factor, in-
terleukin (IL) 7, IL-2, antigen, or other mitogens; Myc is then
present at a low level throughout the cell cycle [18]. Perhaps
not surprisingly, also enforced Tert expression activates c-myc
[19]. On the other hand, Myc transcription is negatively con-
trolled by cAMP, transforming growth factor L (TGFL), in-
terferon Q, the cyclin-dependent kinase inhibitor p21, the
L-catenin/APC pathway, and other proliferation inhibitors
[20]. The v-Abl tyrosine kinase turns on c-myc through a
pathway involving Ras, Raf, and E2F proteins [21], while
the APC tumor suppressor inhibits induction of c-myc by
the Tcf-4 transcription factor [20]. The increase in Myc pro-
tein observed as cells enter the G1 phase re£ects both an
increase in transcription and mRNA stability, and a concom-
itant stabilization of the protein [18]. Myc has an half-life of
only 30 min in growing cells and is destroyed via the ubiqui-
tin/26S proteasome pathway; its stability is controlled by two
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adjacent N-terminal phosphorylation sites, Ser-62 and Thr-58
[22]. Phosphorylation of Ser-62 stabilizes Myc, while phos-
phorylation of Thr-58, which is dependent on prior Ser-62
phosphorylation, promotes its degradation. The transient ac-
cumulation of Myc in G1 is ensured by the interplay of the
two Ras e¡ector pathways Raf/ERK and PI3K/AKT, operat-
ing at di¡erent times. Activation of Ras signalling stabilizes
Myc via ERK phosphorylation of Ser-62 and via the inhibi-
tion of GSK-3 activity by the AKT pathways; at later times,
when Ras signaling weakens, AKT activity declines and GSK-
3 phosphorylates Thr-58, destabilizing Myc. Interestingly,
ERK phosphorylation also stabilizes c-Jun, which contains a
sequence of six amino acids that exactly matches that sur-
rounding the two phosphorylation sites in Myc [22].
The region including the two sites appears to be relevant for
Myc oncogenic properties, since it is a mutational hotspot for
myc alleles in Burkitt’s lymphomas, AIDS lymphomas, and
mouse plasmacytomas, with the majority of mutations a¡ect-
ing Thr-58 [23]. However, most of the mutations, with the
exception of a lymphoma-derived Thr58Ala mutation, do
not a¡ect either Myc apoptosis or transformation of tissue
culture cells.
4. Control of G1 progression by Myc
It has been well documented that ectopic Myc expression
induces quiescent ¢broblasts to enter the cell cycle, reduces G1
duration, and promotes S phase entry; conversely, down-reg-
ulation of Myc expression through an antisense approach has
antiproliferative e¡ects [24]. The simple idea that a critical
gene exists, whose activation explains Myc activity on the
cell cycle, is unrealistic. As a matter of fact, attempts to com-
plement the growth defect in c-myc null ¢broblasts showed
that no single gene, except c-myc itself or N-myc, was able
to restore a normal cell cycle [25]. On the other hand, only the
simultaneous deletion of p107, Rb, and p130 prevents Myc
from stimulating proliferation. It is clear that a complex web
of interactions connects c-Myc to the Rb-regulated restriction
point, a critical decision point in the mammalian cell cycle
(Fig. 2). This network appears to be £exible and robust, so
that disruption of a single component is unable to prevent
Myc action and, conversely, no single target gene can substi-
tute for Myc function.
Myc facilitates G1 exit by positively modulating cyclin/
CDK (cyclin-dependent kinase) complexes, by negatively
modulating the CDK inhibitors p27 and p21, and by interfer-
ing with Rb/E2F activity. A plethora of mechanisms have
been described, mostly derived from overexpression studies,
whose physiological relevance is not always supported by ge-
netic information (Fig. 3).
4.1. Cyclin E complexes
Myc can bypass the p16/Rb growth inhibitory pathway
downstream of Rb activation, with e¡ects indistinguishable
from those of cyclin E, indicating that activation of cyclin
E^Cdk2 kinase complexes is an important step in Myc-in-
duced proliferation. Activation of c-Myc in quiescent ¢bro-
blasts leads to the rapid induction of cyclin E^Cdk2 kinase
activity, while dominant-negative mutant alleles or somatic
c-myc deletion suppress cyclin E^CDK2 activity and may
cause G1 arrest [26]. Although Myc was reported to stimulate
the cyclin E protein synthesis rate and to be involved, together
with E2F, in transcriptional regulation of the cyclin E pro-
moter [27], it appears that the activation of cyclin E^Cdk2
complexes is largely mediated by an action of Myc upstream
of cyclin E.
Fig. 1. Simpli¢ed model of signals modulating Myc expression, and its consequences on growth and proliferation. c-myc transcription is rapidly
induced by a variety of growth factors and mitogenic stimuli, and is repressed by TGF-L and other proliferation inhibitors. The increase in
Myc protein observed as cells enter the G1 phase re£ects an increase in mRNA synthesis, and a concomitant protein stabilization dependent
on Ras-induced phosphorylations via the ERK and PI3K pathways. Induction and repression of key regulators by Myc can lead to coordi-
nated growth and cell proliferation. PDGF: platelet-derived growth factor; M-CSF: multi-colony-stimulating factor; TCR: T cell receptor;
TGF-L : transforming growth factor-L ; ERK: extracellular signal-regulated kinase; PI3K: phosphoinositide 3-kinase.
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4.2. p27 and p21 (kip/cip proteins)
A clue to the mechanism of cyclin E complex activation by
Myc came from the observation that Myc rescues a block
imposed by the Cdk inhibitors p27 and p21. Upon activation
of Myc, p27 is rapidly and transiently sequestered by cyclin
D2^Cdk4 complexes, therefore dissociating from cyclin
E^Cdk2 complexes and allowing their activity [28]. Besides
a¡ecting p27 and p21 activity through sequestration by cyclin
D2^Cdk4 complexes, Myc was recently shown to directly re-
press the expression of p21 [29], and possibly p27 (G. Sonen-
shein, personal communication), and to induce expression of
Cul1 [30]. Cul1 is a critical component of the ubiquitin ligase
complex SCF^SKP2, which promotes selective proteolysis of
p27; SKP2-mediated ubiquitination appears to depend on
phosphorylation of p27, by cyclin E^Cdk2 complexes. Since
degradation of p27 occurs at the G1/S transition, Cul1 regu-
lation may be a critical point through which Myc promotes
G1 exit.
However important, inhibition of p27 does not appear to be
the only rate-limiting cell cycle target of Myc since p21/p27-
de¢cient ¢broblasts are still sensitive to cell cycle regulation
by Myc. However, mice deleted for genes of the three pocket
proteins (Rb, p107, p130) are insensitive, indicating that Myc
activates cyclin E by directly targeting Rb family members
[31].
4.3. Cyclin D complexes
Furthermore, genetic evidence from Myc or cyclin D null
cells strongly supports that cyclin D^Cdk complexes are tar-
gets for Myc-induced proliferation [26,32]. A 12-fold reduc-
tion in the activity of these complexes is the largest defect in a
c-myc3/3 cell line during the G0^S transition; mouse embryo
¢broblast cells lacking either D1 or D2 are unable to activate
cyclin E complexes through overexpressed Myc. Moreover,
cyclin D2-de¢cient primary ¢broblasts undergo accelerated
senescence in culture and are not immortalized by Myc [32].
Recently, independent studies showed that Myc induces an
increase in the amount of cyclin D1, cyclin D2, and CDK4.
Induction of cyclin D1 and D2 leads to sequestration of the
inhibitors p27 and p21. Myc up-regulates D2 mRNA, while
D1 appears to be a¡ected post-transcriptionally, and D3 is
una¡ected by Myc; up-regulation of cyclin D2 in response
to activation of Myc occurs by derepression of a Mad/Max-
mediated inhibition of the D2 promoter [32]. An increase in
CDK4 mRNA levels following activation of conditional Myc
was observed in human umbilical vein cord cells, but not in
Rat-1 cells [33], and the CDK4 protein did not appear to be
limiting for cell cycle progression in c-myc null ¢broblasts [26].
Myc was also found to repress the expression of p15ink4b, an
inhibitor of cyclin D^Cdk4 complexes (M. Eilers, personal
communication).
Cyclin D^Cdk4 and ^Cdk6 serve two functions: a catalytic
one causing the initial Rb phosphorylation in G1, and a sec-
ond function involving sequestration of the cip/kip proteins.
Cyclin D^kinase and cyclin E^kinase complexes compete for
binding to p21 and p27, which have opposite e¡ects on the
two complexes. They inhibit cyclin E complexes, while they
are essential for cyclin D complex assembly. The p27/p21
sequestration function of D cyclins appears to be crucial for
activation of cyclin E^Cdk2 and stimulation of cell prolifer-
ation by Myc, while the kinase activity associated with D
cyclins is not limiting [32]. An interesting possibility is that
the cyclin D^Cdk4 kinase activity may have a role in other
Myc responses, such as cell growth stimulation, since in Dro-
sophila these complexes directly a¡ect both the cell cycle, via
Rb, and growth, via unknown targets [34].
4.4. Cdc25a
The Cdc25a phosphatase is involved in the progression
from G1 to S phase and is thought to control activity of cyclin
E^Cdk2 complexes. It is unclear whether direct upregulation
of Cdc25a mRNA by Myc represents a critical step for Myc
regulation of the cell cycle since, in certain contexts, Cdc25a
appears not limiting for cyclin E^Cdk2 complex activation.
Cdc25a transcription appears to be indirectly regulated by
Myc in some cell lines, for instance through the inactivation
of Rb family proteins, which repress the Cdc25a promoter
[35].
4.5. Rb and Id2
The HLH protein Id2 is largely increased in neuroblasto-
mas, possibly as an epigenetic mechanism to bypass the tumor
suppressor function of Rb. Id2 induction by Myc [36] may
represent a physiologically relevant component of the circuit
connecting Myc and Rb, as two phenotypic hallmarks of Myc
activation, the ability to promote cell cycle reentry in the
absence of growth factors and the ability to cooperate with
Ras to transform ¢broblasts, are dependent on the presence of
Id2. This protein physically associates with active, hypophos-
phorylated forms of the pocket proteins. Experiments
with genetically modi¢ed MEFs (mouse embryo ¢broplasts)
showed that Myc must induce Id2 to overcome a Rb block on
Fig. 2. Schematic representation of Myc-activated and -repressed
pathways a¡ecting cell cycle progression in mammalian cells.
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cell cycle progression; if the Id2-Rb pathway is removed,
other Myc targets are su⁄cient to promote cell cycle progres-
sion. The Id2 mRNA is directly upregulated by Myc tran-
scription factors: c-Myc binding to the Id2 promoter in vivo
occurs after stimulation with serum of quiescent ¢broblasts
[36].
5. Regulation of transcription
The current model is that Myc exerts its biological activities
by regulating gene expression at the transcriptional level. This
poses the identi¢cation of Myc target genes as a central ques-
tion, together with a second one: how can Myc, as a single
protein, have so many functions? In a sense, Myc resembles a
nuclear counterpart of the Ras oncoprotein, recruited by dif-
ferent modules to signal a multiplicity of responses. By anal-
ogy, Myc may be viewed as a nodal element of one, or pos-
sibly more, functional units that implement instructions from
a variety of inputs within the nucleus. Any given outcome
would critically depend on the particular interactions estab-
lished within a network of Myc interacting proteins, in a
dynamic way.
Fig. 3. Myc targets for control of G1 progression. G1 progression is controlled by the CDK complexes cyclin D^Cdk4 (or Cdk6) and cyclin
E^Cdk2: both are rate-limiting for the G1^S transition (reviewed in [55]). Myc may a¡ect G1 progression through multiple mechanisms:
(a) direct repression of p21, and possibly p27, gene transcription [29]; (b) induction of cul1, a cullin family gene encoding a critical component
of the ubiquitin ligase SCF^SKP2, which promotes proteolysis of p27 [30]; (c) increase in CDK4 mRNA levels [33] ; (d) induction of cyclin D2
mRNA and cyclin D1 protein synthesis rate [32]. Besides facilitating the activation of cyclin E^Cdk2 complexes through p21 and p27 sequestra-
tion, cyclin D^Cdk4 complexes may have a direct role in promoting cell growth [34]; (e) up-regulation of Cdc25a mRNA, encoding a phospha-
tase involved in activation of cyclin E^Cdk2 complexes [14] (Myc may a¡ect Cdc25a transcription also indirectly, by inactivation of the pocket
proteins; see f); (f) transcriptional induction of Id2, which may facilitate cyclin E transcription by inactivating Rb [36].
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It is clear that two regions of the Myc protein are essential
for its biological functions: the C-terminal bHLHZip domain,
and an N-terminal ‘activation’ domain (Fig. 4).
The bHLHZip domain consists of two K-helices, basic re-
gion plus helix 1 and helix 2 plus leucine zipper, separated by
a loop of variable length. The Max dimer crystal structure
showed that bHLHZip domains associate in a characteristic
four-helix bundle fold, a structure shared by the bHLH pro-
tein family [37]. The two basic regions diverge from the bun-
dle to contact DNA; three amino acids in the basic region
contact DNA bases, while the loop and the N-terminus of
helix 2 bind to the phosphate backbone. Helices 1 and 2 of
each monomer form a hydrophobic core that stabilizes the
dimeric structure, while the leucine zipper regions form a
coiled coil ; the zipper interactions determine dimerization spe-
ci¢city [38]. The Myc/Max dimer structure is very similar to
Max dimers (Nair, personal communication). Myc interaction
with Max appears to be required for binding to the E box and
for transcriptional activation, since arti¢cial Myc homodimers
are unable to bind the core sequence and are defective in
biological function [38]. How speci¢c recognition of a Myc/
Max target gene is achieved is not fully understood. The tar-
get E box sequence CACGTG de¢ned by in vitro selection is
very frequent in the genome, occurring approximately every
4000 bp; target sequences become even more frequent, one
every 1000 bp, if one takes into account the non-canonical E
boxes shown to be associated with Myc/Max in vivo [39].
Some speci¢city for DNA target recognition comes from the
nucleotides £anking the core sequence, since Myc/Max dimers
show a preference for GC residues immediately adjacent to
the E box [30,39]. Moreover, structural studies indicate that
the sequence speci¢cally recognized by a Max dimer, and
likely by a Myc/Max heterodimer, is eight nucleotides long,
as it includes the core sequence plus the two adjacent nucleo-
tides. Interaction between the loop and nucleotides outside the
E box may further contribute to target recognition speci¢city,
as suggested by the observation that a single lysine residue in
the loop of the bHLH protein Deadpan greatly a¡ects DNA
binding [40]; the corresponding lysine in Max contacts the
DNA phosphate backbone in a region outside the E box.
Cooperativity of multiple E boxes within a promoter or com-
binatorial mechanisms involving association of an E box with
the target sequence for another transcription factor may also
a¡ect binding a⁄nity or speci¢city for subsets of target genes.
Accessibility of target sequences is also likely to play a role:
methylation of CpG within the consensus E box may a¡ect
DNA binding [41], and the binding sites can be obstructed by
abundant bHLHZip proteins like Mnt and USF that recog-
nize the same target sequence [14]. Although target recogni-
tion by Myc/Max and Max/Mad dimers appears very similar
in vitro, there are di¡erences in the basic regions of Myc and
Mad; the third amino acid residue, which varies among Myc,
Mad, and Max basic regions, was reported to give speci¢city
for recognition of nucleotides £anking the E box. Myc binds
ine⁄ciently when the £anking nucleotide is A or T, while Mad
appears to have little speci¢city; so Myc/Max and Mad/Max
appear to have both common and speci¢c targets [30].
Myc behaves as a weak activator and a weak repressor of
transcription on di¡erent targets, and a unifying view of its
transcriptional activity is not yet possible. DNA binding is
clearly required, but the mechanism whereby Myc recruitment
to a promoter results in transcriptional regulation is unclear.
Work on the cyclin D2 promoter suggested that activation by
Myc might work mainly through derepression; full transcrip-
tional activation would depend on other sequence-speci¢c fac-
tors. The transcriptional regulatory activities reside in the ¢rst
143 amino acids of Myc, which include the two evolutionarily
conserved regions MbI and MbII (Myc box I and II; Fig. 4).
The identi¢cation of factors bound to MbII is providing an
insight into the mechanism of transcriptional regulation by
Myc. One such factor is TRRAP, which is necessary for cell
transformation by Myc and has homology to the PI3K/ATM
family, although it lacks kinase activity. The yeast TRRAP is
a subunit of SAGA and NuA4 chromatin remodelling com-
plexes; in mammalian cells, Myc can recruit the histone ace-
tylase GCN5 through TRRAP, indicating that it may be in-
volved in chromatin-dependent activation [42]. In fact, Myc/
Max association with the cyclin D2 promoter is correlated
with hyperacetylation, while acetylation is decreased upon
Max/Mad binding following di¡erentiation stimuli (B. Lu«sch-
er, personal communication). However, whether Myc induces
histone acetylation of a target promoter or whether it binds to
promoters that are already acetylated is far from being estab-
lished. Studies on the Myc target genes cad, which displays
cell cycle-dependent Myc binding, and tert showed that c-Myc
or N-Myc binding does not in£uence the amount of acetylated
histones on the promoter ([43] and P. Farnham, personal
communication). It is possible that, on these targets, TRRAP
has no signi¢cant role and Myc may a¡ect initiation or elon-
gation by modifying the RNA polymerase II activity. MbII
also associates with Tip48 and Tip49 [44], two ATPases/heli-
cases involved in oncogenic transformation and apoptosis by
Myc, but not in cell cycle progression. Other proteins have
been associated with the Myc activation domain, but the sig-
ni¢cance of the interaction remains to be elucidated (see [45]
for review). Modulation of chromatin structure likely impli-
cates the bHLHZip domain as well, which directly interacts
with hSNF5, a component of the SWI/SNF ATP-dependent
chromatin remodelling complex [46]; the c-Myc interaction
with an ATPase associated with the SWI/SNF complex was
also observed (B. Amati, personal communication).
The mechanism of transcriptional repression by Myc is even
more elusive and is likely to di¡er among di¡erent promoters,
as there is no consensus on the speci¢c DNA sequence in-
volved or on interactions with speci¢c proteins. Initiator ele-
ments, which are present in some of the Myc-repressed genes,
bind proteins like YY-1 and Miz-1 that may interact with the
Myc bHLHZip domain [14,45]. On the other hand, repression
might be achieved indirectly, through deactivation of a pos-
itive regulator. Formation of a Myc^Miz-1 complex at the
initiator element was found to correlate with the ability of
an overexpressed Myc to prevent p15ink4b induction by
Miz-1 (M. Eilers, personal communication).
6. Target genes?
A systematic identi¢cation of Myc-regulated genes may rep-
resent the most valuable information to understand how in-
tracellular pathways involved in proliferation, apoptosis,
growth, and transformation are a¡ected by Myc’s activity.
This task has been elusive for a number of reasons, not least
the fact that ectopic Myc expression usually induces only a
two- to three-fold change in transcription of proposed targets.
The criteria for de¢ning a Myc target gene are also contro-
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Table 1
Summary of genes directly regulated by Myc
Gene Criteria
Induced genes
Cell cycle
CCND2 (cyclin D2) cell cycle regulator [29] Microarray
GOS2 (lymphocyte G0/G1 switch gene 2) [29] Microarray
CksHs2 homolog of yeast cdks binding protein [29] Microarray
Cdk4 cell cycle regulator [33] SAGE
Id2 cell cycle regulator [36] Knock-out studies; chromatin Ip
Cdc25A, phosphatase cell cycle regulator [49] Promoter studies
HGF (hepatoma-derived growth factor) growth factor [29] Microarray
Death, immortality
API2 inhibitor of apoptosis [30] Microarray
TRAP1 (tumor necrosis factor receptor-associated protein) [29] Microarray
TERT (telomerase reverse transcriptase) chromosome integrity
[30,56]
Northern
Growth, metabolism, adhesion, etc.
ODC (ornithine decarboxylase) polyamine biosynthesis [29,48,49] Microarray
IARS (isoleucine tRNA synthetase) [29] Microarray
AHCY (S-adenosylhomocysteine hydrolase) [29] Microarray
ASS (argininosuccinate synthetase) [29] Microarray
ECA39 amino acid transport [48,49] RNA subtraction hybridization
Cad pyrimidine biosynthesis [43,48,49] myc3/3 cells ; chromatin Ip
GRPE molecular chaperone [30] Microarray
EST highly similar to GRPE protein homolog precursor [29] Microarray
FABP5 (psoriasis-associated fatty acid binding protein) [29] Microarray
SLC16A1 (solute carrier family 16) [29] Microarray
UMPS metabolism [30] Microarray
TFRC (transferrin receptor) iron metabolism [29] Microarray
IRP2 (iron regulatory protein 2) iron metabolism [54] RNA subtraction hybridization
LDH-A, glucose metabolism [52] Representational di¡erence analysis
GLUT1 (glucose transporter) glucose metabolism [53] Run-on, Northern, results in myc3/3 cells
PFK (phosphofructokinase) glucose metabolism [53] Northern and results in myc3/3 cells
Enolase glucose metabolism [53] Northern and results in myc3/3 cells
TOP1 (topoisomerase) DNA modi¢cation [30] Microarray
DDX18 (MrDb, dead-box helicase) RNA helicase [30,39,49] Microarray
SNRPD1 (small nuclear ribonucleoprotein) [30] Microarray
Fibrillarin rRNA metabolism [29] Microarray
Nucleolin rRNA metabolism [29,51] Microarray
BN51 RNA polymerase III cofactor [51] Run-on and Northern
BLMH drug resistance [30] Microarray
RPIA [30] Microarray
CTIP transcription corepressor [30] Microarray
EIF5A (eukaryotic translation initiation factor 5A) protein synthesis [29] Microarray
EIF4E (translation initiation factor 4E) protein synthesis [14,48,49] Northern and promoter studies
EIF2K (translation initiation factor 2K) protein synthesis [14,48] Northern and promoter studies
Cul1, component of the ubiquitin ligase SCFSKP2 complex [30] Microarray
ZRP1, cytoskeletal protein [30] Microarray
FKBP52 (FK506 binding protein) immunophilin [29] Microarray
PPIF (peptidyl-prolyl cis-trans isomerase F) immunophilin [29] Microarray
K-Prothymosin [47,48] Promoter studies
C/EBPK (CCAAT enhancer binding protein) transcription factor [48] Promoter studies
HMG-I/Y chromatin binding protein [57] Promoter studies
Repressed genes
Cell cycle
CCNG2 cell cycle regulator [30] Microarray
CHES1 cell cycle checkpoint regulator [30] Microarray
CDKN1A (p21) cyclin-dependent kinase inhibitor
[29]
Microarray
(p27, cyclin-dependent kinase inhibitor) (G. Sonenshein, personal communication)
GADD45 related to growth arrest [48,49] myc3/3 cells, promoter studies
Gas1 (membrane-associated protein) related to growth arrest [30] Microarray
CTGF (connective tissue growth factor) growth factor [29] Microarray
IGF2R (IGF2 receptor) growth factor receptor [30] Microarray
PDGFRA (PDGF receptor K) growth factor receptor [29] Microarray
Myc transcription factor [30] Microarray
Growth, metabolism, adhesion, etc.
H-ferritin (heavy subunit of ferritin) [54] RNA subtraction hybridization
THBS1 (thrombospondin 1) angiogenesis [30] Microarray
COL3A1 (K-1 type 3 collagen) adhesion molecule [29] Microarray
FN1 (¢bronectin 1) adhesion molecule [29] Microarray
TPM1 (tropomyosin K chain) (skeletal muscle) [29] Microarray
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versial : ¢nding a Myc^Max binding site on a promoter and
showing that it confers a Myc transcriptional response in
transient assays is not su⁄cient; additional evidence for spe-
ci¢city, the correlation of expression kinetics with those of
Myc, and the demonstration that the endogenous gene can
be induced by Myc are important (reviewed in [47,48]). Since
Myc stimulates proliferation and cell growth, the levels of
many genes are predicted to change indirectly as a conse-
quence of these processes; requirement of de novo protein
synthesis is an important criterion for discriminating among
direct and indirect targets. Initially, target genes were identi-
¢ed by di¡erential hybridization or by guessing. Many have
been validated by way of induction of an overexpressed Myc^
ER (a Myc fusion to a mutated estrogen receptor) ; there is
not a general consensus that this is a valid criterion, since
overexpression may cause artifacts. The alternative approach
to look at gene expression changes in Myc null cells did not
settle the issue, as it was shown that only two genes (cad and
gadd45) out of 11 proposed Myc targets were deregulated in
c-Myc null Rat-1 ¢broblasts [49]. In vivo chromatin immuno-
precipitation is also an important element for target valida-
tion. Of course the most important discriminant is to establish
a role of the ‘target’ as mediator of Myc biological activities.
Genome-wide expression analysis through cDNA or oligo-
nucleotide microarrays is expected to clarify the connections
between transcriptional activity and biological functions of
Myc. Changes in gene expression upon tamoxifen activation
of a Myc^ER chimera have been investigated in human ¢bro-
blasts, with microarrays of 5272 and 6416 sequences [29,30].
Altogether, 56 genes were found to be directly activated or
repressed; no large e¡ect on activation or repression of any of
the monitored genes was observed, in accordance with the
relatively weak transcriptional activity of Myc. This indicates
that the number of genes directly modulated by Myc in these
experimental conditions would be above 500 on a genome
basis, a ¢gure that might be underestimated, as it is unclear
how e⁄ciently low-abundance mRNAs, such as TERT, are
detected. The number of ‘targets’ could grow to even more
confusing dimensions when di¡erent culture conditions, favor-
ing for instance apoptosis rather than proliferation, are taken
into account. As a matter of fact, microarray pro¢ling per-
formed in cells deprived of serum has revealed targets di¡er-
ent from those identi¢ed in growth medium, possibly since
Myc acts as an apoptosis inducer in this case [50].
From a survey of the putative direct targets identi¢ed so far
(Table 1), it is not evident that Myc may be at the top of a
speci¢c regulatory cascade since, paradoxically, it appears dif-
¢cult to identify a cellular function not a¡ected by Myc.
Cell growth stimulation by Myc is in agreement with the
role that many target genes have in ribosome biogenesis, pro-
tein synthesis, and generally in cell metabolism. They include
translation initiation factors (EIF4E, EIF5A), the three nucle-
olar proteins ¢brillarin, BN51, and nucleolin, ribosomal pro-
teins (Rps11), the RNA helicase MrDb (DDX18), and ODC
(polyamine biosynthesis) [14,29,30,51]. Myc in£uences the
metabolic pathways involved in glucose uptake and iron ho-
meostasis, respectively, through upregulation of the glycolytic
genes LDH-A (lactate dehydrogenase), GLUT1 (glucose
transporter), PFK (phosphofructokinase), enolase A, and
through upregulation of IRP2 (iron regulatory protein 2)
and repression of H-ferritin [52^54].
Repression of genes involved in cytoskeletal structure and
cell adhesion, such as ¢bronectin, collagen, tropomyosin, and
the antiangiogenic factor thrombospondin, may contribute to
altered shape and adhesiveness of transformed cells.
Several cell cycle-related genes were detected from micro-
arrays, SAGE, or knock-out studies as novel targets for acti-
vation (CksHs2, Cdk4, Id2) or repression (p21, Ches1, and
CCNG2), besides old Myc targets like cyclin D2, Gadd45,
and Gas1.
The presence of genes potentially involved in apoptosis
(AP12, TRAP1) among direct Myc targets in growing
cells is insu⁄cient to explain how Myc a¡ects cell death. By
gene expression pro¢ling in conditions that favor apoptosis in
a myeloid cell line, other transcripts were identi¢ed as regu-
lated by Myc, either directly or indirectly [50]. Up-regulated
transcripts included those for Ca2 channel L3 subunit, plate-
let factor 4 precursor, myeloperoxidase, extracellular matrix
protein 1, CD9, SM-20, Spi-2 protease inhibitor; genes en-
coding GATA binding protein 2, L2-integrin and chemokine
(C-C) receptor 2 are, instead, among the down-regulated
genes.
Growth factors, receptors, transcriptional regulators, DNA
topoisomerase I, HMGI/Y, and other genes whose activity is
di⁄cult to rationalize in relation to Myc are also in the ex-
panding list of direct Myc targets.
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